Help shape tumour profiling tests in Scotland to inform chemotherapy decisions

What’s the project about?

In Scotland there are a number of tumour profiling tests available such as Oncotype DX, MammaPrint, EndoPredict and Prosigna. They are used for patients with oestrogen receptor positive  or HER2 negative primary breast cancer which is either lymph node negative or positive.

Tumour profiling tests can be used for making chemotherapy decisions for people with early stage breast cancer.

The Scottish Health Technology Group (SHTG) are reviewing this use of tumour profiling tests. This will help then produce guidance on chemotherapy decisions for breast cancer patients to improve treatment and outcomes.

Breast Cancer Now have been asked to provide information about the patient experience, and would like to hear from you.

Who can take part?

Anyone who has had a tumour profiling test after a diagnosis of either

• oestrogen receptor positive primary breast cancer,

OR

• HER2 negative primary breast cancer

This can be either lymph node negative or positive.

Although this review is being undertaken by a Scottish organisation, we'd be happy to hear from people across the UK.

Why do you want me to be involved?

By sharing your insight with Breast Cancer Now, you’ll be ensuring that our contribution to this work is patient centred and meaningful. This will ensure that any recommendations that are made as a result of this project about the use of tumour profiling tests are responding to patient needs.

What will you ask me to do?

You'll be asked to complete a short online form sharing your experiences of tumour profiling tests.

You can contact Anne-Marie to get a link to the form. Or, if you’d prefer, you can talk to her directly to share your experiences.

You can also find out more about the assessment of tumour profiling tests and the wider work of Scottish Health Technologies Group.